Integrin linked kinase modulation of monocyte activation
View Patent ↗Methods are provided to specifically modulate the activation of monocytes and/or macrophages. Administration of integrin linked kinase (ILK) blocking agents; compounds that otherwise prevent the binding of natural ILK ligands to ILK; or compounds that prevent expression of, or signaling through ILK exert an anti-inflammatory effect by inhibiting iNOS and COX-2 expression, at the level of transcription by suppressing the activation of NF-κB. The modulation of activation through ILK is used to regulate immune processes at targeted sites, for example to decrease undesirable inflammatory responses.
1. A method of modulating the activation of monocytes in a mammalian host, the method comprising:
administering an effective amount of an integrin-linked kinase (ILK) inhibitor, in a dose effective to inhibit said activation of monocytes; and
monitoring said monocytes to determine inhibition of activation by determining at least one of: a decrease in monocyte expression of cycloxygenase-2 (COX-2); decrease in monocyte release of interleukin-6 (IL-6); and suppression of nuclear factor-kappa B (NF-κB) activation in monocytes; and
wherein said ILK inhibitor inhibits ILK kinase activity in a cell-free kinase inhibition assay.
2. The method of claim 1 , wherein said administration provides for a prolonged localized concentration of said ILK inhibitor.
3. The method of claim 1 , wherein said host is suffering from an undesirable inflammatory response associated with said monocytes.
4. The method of claim 1 , wherein monitoring said monocytes to determine inhibition of activation comprises determining a decrease in monocyte release of IL-6.
5. The method of claim 1 , wherein monitoring said monocytes to determine inhibition of activation comprises determining a decrease in monocyte expression of COX-2.